Skip to main content

Table 1 Patient characteristics and CEC detection

From: Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy

   Mean CEC level 166 cells/4 mL Range (2–1195 cells/4 mL) Total P a
   ≥ 166 cells/4 mL <166 cells/4 mL   
   CEChigh CEClow   
   12 25 37  
Age Over 70 8 10 18 (49%) 0.17
  Below 70 4 15 19 (51%)  
Sex Male 7 17 24 (65%) 0.72
  Female 5 8 13 (35%)  
Stage III 3 11 14 (38%) 0.59
  IV 8 12 20 (54%)  
  Recurrence 1 2 3 (8%)  
ECOG PS 0 5 18 23 (62%) 0.09
  1 6 4 10 (27%)  
  2 1 3 4 (11%)  
Pancreatic tumor location Head 5 12 17 (46%) >0.9
  Body 5 9 14 (38%)  
  Tail 2 4 6 (16%)  
CA19-9 (U/mL) ≥10,000 3 5 8 (22%) >0.9
  < 10,000 9 20 29 (78%)  
CRP (mg/dL) ≥1.0 7 3 10 (27%) <0.01
  <1.0 5 22 27 (73%)  
Histology Poorly differentiated 5 9 14 (38%) 0.62
  Moderately differentiated 4 10 14 (38%)  
  Adenosquamous 1 0 1 (2%)  
  N.E (cytology only) 2 6 8 (22%)  
Tumor response Partial response 2 2 4 (11%) <0.05
  Stable disease 4 18 22 (59%)  
  Progressive disease 6 5 11 (30%)  
Second line therapy S-1 6 12 18 (49%) 1
  Oxaliplatin + S-1 0 2 2 (5%)  
  No 6 11 17 (46%)  
  1. a P values were calculated for each variable using Fisher’s exact test.
  2. Abbreviations: CEC = circulating endothelial cell; ECOG = Eastern Cooperative Oncology Group; CA19-9 = carbohydrate antigen 19–9; CRP = C-reactive protein.